Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
APIs | cGMP Manufacture | Cytotoxics and High Potency Manufacturing
CDMO Market Trends
Vivek Sharma of Piramal Pharma Solutions discusses outsourcing trends, opportunities, and the capabilities needed for today’s pharma/biopharma pipelinesOnline Exclusives Kristin Brooks, Contract Pharma 02.12.19
-
Cytotoxics and High Potency Manufacturing
High Containment & Cost Savings with Single Use Isolator Technology
The trend towards HPAPIs is driving the need for innovative containment systems.Online Exclusives Scott Patterson, Vice President Commercial Sales, ILC Dover 01.31.19
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development
CDMOs On The Rise
Tracking growth and strategies in the CDMO businessMichel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Baxter, Oasmia Ink Apealea Commercial Mfg. Pact
Apealea will be manufactured at Baxter’s cytotoxic manufacturing site in Germany12.07.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News | Inspections | QA/QC | Regulatory Affairs
Recipharm Audit Results in Licence Restriction
Five non-critical highly potent products from the Ashton-u-Lyne, UK site suspended due to potential cross contamination risk10.25.18
-
Cytotoxics and High Potency Manufacturing
HPAPI Technology Trends
Expanding HPAPI sector driving innovation in containment technologyMichael Avraam, Global Product Manager, ChargePoint Technology 10.10.18
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
IDIFARMA Adds Spray Drying for Highly Potent Drugs
GEA Niro Mobile Minor equipment up to Category 4 OEL/OEB now operational10.08.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Cambrex Upgrades API Mfg. Facilities in Milan
$3 million investment will include installation of new 12,000 liter reactor10.08.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Expands HPAPI Capacity
Will add two new manufacturing suites at its Visp site for the manufacture of ADC payloads10.08.18
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Evonik Completes €36M Expansion
Adds HPAPI, mPEGs and continuous processing at multiple production sites in the U.S. and Europe09.19.18
-
APIs | Cytotoxics and High Potency Manufacturing
HPAPI Technology Evolution
Handling of high potency compounds for API and DP from development on a laboratory scale and scale-up to commercial.Martina Kotthaus, Jeff Dinyer, Anil Kane and Marvin Faber, Patheon, part of Thermo Fisher Scientific 09.11.18
-
APIs | Cytotoxics and High Potency Manufacturing
HPAPI Market Trends
Rising demand for targeted cancer and other treatments driving HPAPI growth.Nigel Walker, That’s Nice/Nice Insight 09.11.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Excipients | Facilities | Industry News
AGC Expands CDMO Services
Increases GMP-compliant synthetic pharmaceutical intermediate and active ingredient production capacity tenfold07.12.18
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
Minakem to Open New Containment Facility for HPAPI Production
CDMO has entered final qualification run for a new closed-controlled environment production facility in BelgiumVideos
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Scale-up/Technology Transfer
Cambrex Invests $5M in New Lab Expansion
To add capability and capacity at Karlskoga, Sweden facility05.31.18
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development | Industry News
Cambrex Completes Pilot Plant Expansion at High Point
Begins construction of a new $24 million facility at Charles City, IA plant for the manufacture of HPAPIs05.15.18
-
Cytotoxics and High Potency Manufacturing | Industry News
PCI Launches High Containment Packaging at Ireland Site
Latest strategic initiative expands High Containment Operations services04.25.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Idifarma Expands High Potent Capabilities
Niche CDMO adds spray drying for highly potent drugs03.29.18
-
Analytical Services | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
PCI Bolsters Analytical Capabilities
Significant expansion of analytical laboratories at its center of excellence for contained manufacturing03.20.18
